{"id":22681,"date":"2023-02-09T11:02:06","date_gmt":"2023-02-09T10:02:06","guid":{"rendered":"https:\/\/kymos.com\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/"},"modified":"2023-02-09T11:02:06","modified_gmt":"2023-02-09T10:02:06","slug":"un-metode-lc-ms-ms-per-a-quatre-cannabinoides","status":"publish","type":"post","link":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/","title":{"rendered":"Un m\u00e8tode LC-MS\/MS per a quatre cannabinoides"},"content":{"rendered":"<p><span style=\"font-size: 14pt;\">El c\u00e0nnabis i el seu \u00fas medicinal fa temps que s\u00f3n objecte de debats entre la comunitat m\u00e8dica i han estat repetidament reclamats per les associacions de pacients. Tanmateix, el c\u00e0nnabis era il\u00b7legal en molts pa\u00efsos i estava classificat com a droga d&#8217;ab\u00fas. En els darrers anys, la perspectiva sobre el c\u00e0nnabis ha canviat i el 2015 la FDA va flexibilitzar els requisits reglamentaris per permetre als investigadors dur a terme assajos amb CBD (cannabidiol). A finals del 2020, el Tribunal de Just\u00edcia de la Uni\u00f3 Europea va dictaminar que el CBD no \u00e9s un estupefaent i, unes setmanes m\u00e9s tard, la Comissi\u00f3 d&#8217;Estupefaents de l&#8217;ONU va votar per reclassificar el c\u00e0nnabis de la Llista IV a una categoria menys nociva.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Tenint en compte aquests canvis fonamentals, cada cop m\u00e9s empreses estudien el desenvolupament de medicaments basats en c\u00e0nnabis. Naturalment, aix\u00f2 tamb\u00e9 requereix m\u00e8todes anal\u00edtics fiables, espec\u00edfics i robustos. Jos\u00e9 Antonio Legarreta, expert de Kymos en el desenvolupament de m\u00e8todes LC-MS\/MS, informa:  <\/span><\/p>\n<blockquote><p><span style=\"font-size: 14pt;\">\u201cKymos ha desenvolupat un m\u00e8tode LC-MS\/MS per als principals metab\u00f2lits actius del cannabidiol (CBD) i el CBD que ha demostrat ser selectiu, lineal i complir els requisits bioanal\u00edtics de precisi\u00f3, exactitud i efecte matriu.\u201d<\/span><\/p><\/blockquote>\n<p><span style=\"font-size: 14pt;\">Els cannabinoides s\u00f3n subst\u00e0ncies que es troben a la planta de c\u00e0nnabis i que actuen sobre receptors espec\u00edfics al cervell i al cos humans. S\u00f3n els principals ingredients actius tant dels productes medicinals derivats del c\u00e0nnabis com dels preparats de c\u00e0nnabis. Els dos m\u00e9s estudiats s\u00f3n el tetrahidrocannabinol (THC) i el cannabidiol (CBD).  <\/span><\/p>\n<blockquote><p><span style=\"font-size: 14pt;\">\u00abEn aquest m\u00e8tode ens hem centrat en el CBD i els seus principals metab\u00f2lits\u00bb, explica Jos\u00e9 Antonio. \u00abHem aconseguit desenvolupar un \u00fanic m\u00e8tode LC-MS\/MS per a la determinaci\u00f3 simult\u00e0nia del cannabidiol (CBD) i els principals metab\u00f2lits del CBD (\u03949-THC, 11-hidroxi-\u03949-THC i 11-nor-9-carboxi-\u03949-THC) en plasma hum\u00e0. Basada en 200 \u00b5L de mostra de plasma i un procediment senzill de precipitaci\u00f3 de prote\u00efnes mitjan\u00e7ant plaques d&#8217;eliminaci\u00f3 de fosfol\u00edpids, la determinaci\u00f3 LC-MS\/MS es duu a terme mitjan\u00e7ant un Sciex 6500+ Tripe Quadrupole (mode MRM). El m\u00e8tode ha demostrat ser selectiu, lineal i compleix els requisits bioanal\u00edtics de precisi\u00f3, exactitud i efecte matriu. Finalment, estem orgullosos d&#8217;haver aconseguit rangs m\u00ednims de calibratge amb el nostre m\u00e8tode:\u00bb    <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">CBD: 0,05-50 ng\/mL<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">\u03949-THC: 0,05-50 ng\/mL<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">11-Hidroxi-\u03949-THC -THC: 0,1-100 ng\/mL<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">11-nor-9-carboxi-\u03949-THC: 0,2-200 ng\/mL\u201d<\/span><\/p><\/blockquote>\n<p><span style=\"font-size: 14pt;\">Per descomptat, no s&#8217;acaba aqu\u00ed. Al departament de bioan\u00e0lisi de Kymos Group treballem cada dia per desenvolupar m\u00e8todes LC-MS\/MS m\u00e9s sensibles, que s&#8217;adapten perfectament al projecte de cada client.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Si necessiteu ajuda amb els vostres projectes de cannabinoides o amb el desenvolupament de m\u00e8todes LC-MS\/MS, poseu-vos en contacte amb <a href=\"mailto:commercial@kymos.com\" data-wpel-link=\"internal\">commercial@kymos.com<\/a> . Estarem encantats de proporcionar-vos un assessorament detallat, preparar un pressupost i dur a terme els vostres projectes de manera fiable i eficient. <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El c\u00e0nnabis i el seu \u00fas medicinal fa temps que  [&#8230;]<\/p>\n","protected":false},"author":7,"featured_media":15294,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[95],"tags":[67],"class_list":["post-22681","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bioanalisi","tag-carles"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Un m\u00e8tode LC-MS\/MS per a quatre cannabinoides | Kymos<\/title>\n<meta name=\"description\" content=\"Kymos ha desenvolupat i validat un m\u00e8tode LC-MS\/MS per als principals metab\u00f2lits actius del cannabidiol (CBD) i del CBD.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un m\u00e8tode LC-MS\/MS per a quatre cannabinoides | Kymos\" \/>\n<meta property=\"og:description\" content=\"Kymos ha desenvolupat i validat un m\u00e8tode LC-MS\/MS per als principals metab\u00f2lits actius del cannabidiol (CBD) i del CBD.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T10:02:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2023\/02\/2023-02-15_Cannabis_Banner_3_small.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1461\" \/>\n\t<meta property=\"og:image:height\" content=\"754\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Carles Celma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Carles Celma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/\"},\"author\":{\"name\":\"Carles Celma\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/3d86e112b87df4b5c1304ce33368ef23\"},\"headline\":\"Un m\u00e8tode LC-MS\\\/MS per a quatre cannabinoides\",\"datePublished\":\"2023-02-09T10:02:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/\"},\"wordCount\":522,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/2023-02-15_Cannabis_Banner_3_small.png\",\"keywords\":[\"carles\"],\"articleSection\":[\"Bioan\u00e0lisi\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/\",\"name\":\"Un m\u00e8tode LC-MS\\\/MS per a quatre cannabinoides | Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/2023-02-15_Cannabis_Banner_3_small.png\",\"datePublished\":\"2023-02-09T10:02:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/3d86e112b87df4b5c1304ce33368ef23\"},\"description\":\"Kymos ha desenvolupat i validat un m\u00e8tode LC-MS\\\/MS per als principals metab\u00f2lits actius del cannabidiol (CBD) i del CBD.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/2023-02-15_Cannabis_Banner_3_small.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/2023-02-15_Cannabis_Banner_3_small.png\",\"width\":1461,\"height\":754},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/ca\\\/inici\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un m\u00e8tode LC-MS\\\/MS per a quatre cannabinoides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#\\\/schema\\\/person\\\/3d86e112b87df4b5c1304ce33368ef23\",\"name\":\"Carles Celma\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g\",\"caption\":\"Carles Celma\"},\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/news\\\/author\\\/dr-carles-celma\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un m\u00e8tode LC-MS\/MS per a quatre cannabinoides | Kymos","description":"Kymos ha desenvolupat i validat un m\u00e8tode LC-MS\/MS per als principals metab\u00f2lits actius del cannabidiol (CBD) i del CBD.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/","og_locale":"ca_ES","og_type":"article","og_title":"Un m\u00e8tode LC-MS\/MS per a quatre cannabinoides | Kymos","og_description":"Kymos ha desenvolupat i validat un m\u00e8tode LC-MS\/MS per als principals metab\u00f2lits actius del cannabidiol (CBD) i del CBD.","og_url":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/","og_site_name":"Kymos","article_published_time":"2023-02-09T10:02:06+00:00","og_image":[{"width":1461,"height":754,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/02\/2023-02-15_Cannabis_Banner_3_small.png","type":"image\/png"}],"author":"Carles Celma","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"Escrit per":"Carles Celma","Temps estimat de lectura":"3 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/"},"author":{"name":"Carles Celma","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/3d86e112b87df4b5c1304ce33368ef23"},"headline":"Un m\u00e8tode LC-MS\/MS per a quatre cannabinoides","datePublished":"2023-02-09T10:02:06+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/"},"wordCount":522,"image":{"@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/02\/2023-02-15_Cannabis_Banner_3_small.png","keywords":["carles"],"articleSection":["Bioan\u00e0lisi"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/","url":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/","name":"Un m\u00e8tode LC-MS\/MS per a quatre cannabinoides | Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/02\/2023-02-15_Cannabis_Banner_3_small.png","datePublished":"2023-02-09T10:02:06+00:00","author":{"@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/3d86e112b87df4b5c1304ce33368ef23"},"description":"Kymos ha desenvolupat i validat un m\u00e8tode LC-MS\/MS per als principals metab\u00f2lits actius del cannabidiol (CBD) i del CBD.","breadcrumb":{"@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/02\/2023-02-15_Cannabis_Banner_3_small.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/02\/2023-02-15_Cannabis_Banner_3_small.png","width":1461,"height":754},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/ca\/news\/un-metode-lc-ms-ms-per-a-quatre-cannabinoides\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/ca\/inici\/"},{"@type":"ListItem","position":2,"name":"Un m\u00e8tode LC-MS\/MS per a quatre cannabinoides"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/ca\/#website","url":"https:\/\/kymos.com\/ca\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/kymos.com\/ca\/#\/schema\/person\/3d86e112b87df4b5c1304ce33368ef23","name":"Carles Celma","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f7ec8bcf3304288056fadfac1c80186a100e5bc223991385f6f2e5e4c8a55099?s=96&d=mm&r=g","caption":"Carles Celma"},"url":"https:\/\/kymos.com\/ca\/news\/author\/dr-carles-celma\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/comments?post=22681"}],"version-history":[{"count":0,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/posts\/22681\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media\/15294"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media?parent=22681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/categories?post=22681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/tags?post=22681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}